BCG Therapy for Superficial Bladder Cancer

  • David R. Kelley
  • William J. Catalona
  • Donald L. Lamm
Part of the Cancer Treatment and Research book series (CTAR, volume 19)

Abstract

Many recurrent superficial bladder cancers cannot be controlled with current standard therapies. Transurethral resection of superficial bladder tumors is curative in only 30 to 40% of cases. Adjuvant topical chemotherapy for superficial tumors may increase the cure rate to 60%. Whether topical chemotherapy can prevent the progression of these lesions to higher grades and stages is yet to be determined. There remains a significant percentage of patients (40%) who will suffer from recurrent tumors and possible cancer progression.

Keywords

Tuberculosis Oncol Bacillus Cyclophosphamide Acetaminophen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adolphs H, Bastian H: Chemoimmune prophylaxis of superficial bladder tumors. J Urol 129:29, 1983.PubMedGoogle Scholar
  2. 2.
    Adolphs HD, Bastian HP: Chemoimmune prophylaxis of superficial bladder tumors. Results after treatment of more than 130 patients in four years. Abstract 347. Americal urological association, seventy-eight annual meeting, Las Vegas, Nevada, April, 1983.Google Scholar
  3. 3.
    Antonaci S, Piccinno A, Lucivero G, Miglietta A, Piccininno A, Bonoma L: Effect of BCG immunotherapy on cell mediated cytotoxicity in bladder cancer patients following surgical treatment. Tumori 67:177, 1981.PubMedGoogle Scholar
  4. 4.
    Bloomberg SD, Brosman SA, Hausman MS, Cohen A, Battenberg JD: The effect of BCG on the dog bladder. Invest Urol 12:423, 1975.PubMedGoogle Scholar
  5. 5.
    Brosman SA: Experience with bacillus Calmette-Guerin in patients with superficial bladder cancer. J Urol 128:27, 1982.PubMedGoogle Scholar
  6. 6.
    Brosman SA: Experience with bacillus Calmette-Guerin in patients with superficial bladder cancer. Presented at National Bladder Cancer Conference, Sarasota, Florida, January, 1983.Google Scholar
  7. 7.
    Camacho F, Pinsky CM, Kerr D, Whitmore WF Jr, Oettgen H: Treatment of superficial bladder cancer with intravesical BCG. Abstract C-160, Proc Am Assoc Cancer Res and Am Soc Clin Oncol 21:359, 1980.Google Scholar
  8. 8.
    Douville Y, Pelouze G, Roy R, Charrois R, Kibrite A, Martin M, Dionne L, Coulonval L, Robinson J: Recurrent bladder papillomata treated with bacillus Calmette-Guerin: A preliminary report (phase I trial). Cancer Treat Rep 62:551, 1978.PubMedGoogle Scholar
  9. 9.
    Flamm J, Grof F: Adjuvant local immunotheraphy with bacillus Calmette-Guerin (BCG) in treatment of urothelial carcinoma of the urinary bladder. Wien Med Wochenschr 131:501, 1981.PubMedGoogle Scholar
  10. 10.
    Herr HW, Pinsky CM, Whitmore WF Jr, Oettgen HF, Melamed MR: Effects of intravesical bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder. Cancer 51:1323, 1983.PubMedCrossRefGoogle Scholar
  11. 11.
    Herr HW, Pinsky CM, Whitmore WF Jr, Oettgen HF, Melamed MR: Intravesical bacillus Calmette-Guerin (BCG) therapy of superficial bladder tumors. Abstract 307. American Urological Association, Seventy-eight annual meeting, Las Vegas, Nevada, April, 1983.Google Scholar
  12. 12.
    Herr HW, Whitmore WF Jr, Logsini PC, Pinsky CM: Extravesical carcinoma in situ after intravesical bacillus Calmette-Guerin (BCG). Abstract 346. American Urological Association, Seventy-eighth annual meeting, Las Vegas, Nevada, April, 1983.Google Scholar
  13. 13.
    Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HJ: Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 124:38, 1980.PubMedGoogle Scholar
  14. 14.
    Lamm DL, Thor DE, Winters WD, Stogdill VD, Radwin HM: BCG Immunotherapy of bladder cancer: Inhibition of tumor recurrence and associated immune responses. Cancer 48:82, 1981.PubMedCrossRefGoogle Scholar
  15. 15.
    Lamm D, Thor DE, Stogdill VD, Radwin H: Bladder cancer immunotherapy. J Urol 128:931, 1982.PubMedGoogle Scholar
  16. 16.
    Lamm DL, Stogdill VD, Radwin HM: The current status of BCG in the treatment of human bladder cancer. Abstract 345. American Urological Association, Seventy-eighth annual meeting, Las Vegas, Nevada, April, 1983.Google Scholar
  17. 17.
    Martinez-Pineiro JA, Muntanola P: Non-specific immunotherapy with BCG vaccine in bladder tumors. Eur Urol 3:11, 1977.PubMedGoogle Scholar
  18. 18.
    Martinez-Pineiro JA: BCG vaccine in the treatment of non-infiltrating papillary tumors of the bladder. In: Bladder tumors and other topics in urological oncology, Pavone-Macaluso M, Smith PH, Edsmyr F (eds). New York: Plenum Press, p 175, 1980.Google Scholar
  19. 19.
    Morales A, Eidinger D, Bruce AW: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116:180, 1976.PubMedGoogle Scholar
  20. 20.
    Morales A: Treatment of carcinoma in situ of the bladder with BCG. A phase II trial. Cancer Immunol Immunother 9:69, 1980.CrossRefGoogle Scholar
  21. 21.
    Morales A, Ottenhof P, Emerson L: Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin. J Urol 125:649, 1981.PubMedGoogle Scholar
  22. 22.
    Morales A: Long-term results and complications of intravesical BCG therapy for cancer. Abstract 344. American Urological Association, Seventy-eighth annual meeting, Las Vegas, Nevada, April, 1983.Google Scholar
  23. 23.
    Netto NR Jr, Lemos GC: A comparison of treatment methods for prophylaxis of recurrent superficial bladder tumors. J Urol 129:33, 1983.Google Scholar
  24. 24.
    Shapiro A, Kadmon D, Catalona WJ, Ratliff TL: Immunotherapy of superficial bladder cancer. J Urol 128:891, 1982.PubMedGoogle Scholar
  25. 25.
    Silverberg E, Lubera JA: A review of American Cancer Society estimates of cancer cases and deaths. Cancer 33:2, 1983.Google Scholar
  26. 26.
    Sparks FC: Hazards and complications of BCG immunotherapy. Med Clin North Am 60:499, 1976.PubMedGoogle Scholar
  27. 27.
    Stober U, Peter HH: BCG-Immunotherapie zur Rezidivprophylaxe beim Harnblasenkarzinom? Therapiewoche 30:6067, 1980.Google Scholar
  28. 28.
    Zbar B, Rapp HJ: Immunotherapy of guinea pig cancer with BCG. Cancer 34:1532, 1974.PubMedCrossRefGoogle Scholar

Reference

  1. 1.
    Bloomberg SD, Brosman SA, Hausman MS, Cohen A, Battenberg JD: The effect of BCG on the dog bladder. Invest Urol 12:423, 1975.PubMedGoogle Scholar
  2. 2.
    Brosman SA: Experience with bacillus Calmette-Guerin in patients with superficial bladder cancer. J Urol 128:27, 1982.PubMedGoogle Scholar
  3. 3.
    Ramm J, Grof F: Adjuvant local immunotherapy with bacillus Calmette-Guerin (BCG) in treatment of urothelial carcinoma of the urinary bladder. Wien Med Wochenschr 131:501, 1981.Google Scholar
  4. 4.
    Herr HW, Pinsky CM, Whitmore WF Jr, Oettgen HF, Melamed MR: Intravesical bacillus Calmette-Guerin (BCG) therapy of superficial bladder tumors. Abstract 307. American Urological Association, Seventy-eighth annual meeting, Las Vegas, Nevada, April, 1983.Google Scholar
  5. 5.
    Herr HW, Whitmore WF, Jr, Logsini PC, Pinsky CM: Extravesical carcinoma in situ after intravesical bacillus Calmette-Guerin (BCG). Abstract 346. American Urological Association, Seventy-eighth annual meeting, Las Vegas, Nevada, April, 1983.Google Scholar
  6. 6.
    Lamm DL, Reichert DF, Harris SC, Lucio RM: Immunotherapy of murine transitional cell carcinoma. J Urol 128:1104–1108, 1982.PubMedGoogle Scholar
  7. 7.
    Lamm DL, Harris SC, Gittes RF: Bacillus Calmette-Guerin and dinitrochloride benzene: Immunotherapy of chemically-induced bladder tumors. Invest Urol 14:369, 1977.PubMedGoogle Scholar
  8. 8.
    Minder P: Shared antigens between animal and human tumors and microorganisms in BCG in cancer immunotherapy. In: Jamoureux G, Turcotte R, Portleance V (eds). New York: Grune and Stratton, pp 73–81, 1976.Google Scholar
  9. 9.
    Netto NR Jr, Lemos GC: A comparison of treatment methods for prophylaxis of recurrent superficial bladder tumors. J Urol 129:33, 1983.Google Scholar
  10. 10.
    Robinson JC: Risks of BCG intralesional therapy: An experience with melanoma. J Surg Oncol 9:587–593, 1977.PubMedCrossRefGoogle Scholar
  11. 11.
    Stober U, Peter HH: NCG-Immunotherapy zur Rezidivprophylaxe beim Harnblasenkarzinom? Therapiewoche 30:6067, 1980.Google Scholar
  12. 12.
    Zbar B, Rapp HJ: Immunotherapy of guinea pig cancer with BCG. Cancer 34:1532, 1974.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1984

Authors and Affiliations

  • David R. Kelley
  • William J. Catalona
  • Donald L. Lamm

There are no affiliations available

Personalised recommendations